Stimit AG

Stimit AG is a private, pre-revenue medical device innovator targeting a critical unmet need in respiratory and critical care. The company's core technology is a non-invasive system for transcutaneous diaphragm stimulation, aimed at maintaining diaphragm muscle mass and function in sedated, mechanically ventilated ICU patients to reduce ventilator-induced diaphragm dysfunction (VIDD). By promoting a more natural, diaphragm-driven breath, Stimit's approach has the potential to shorten ventilation time, decrease ICU complications, and improve patient outcomes. The technology is currently in development, with no approved products on the market as of the provided information.

Non-invasive, transcutaneous electrical stimulation technology designed to activate the diaphragm and phrenic nerves to maintain muscle function in mechanically ventilated patients.

The field of diaphragm pacing is small, with existing solutions primarily being invasive (surgically implanted). Stimit's main competition is the current standard of care—sedation and controlled mechanical ventilation—and potentially other novel pharmacological or device-based approaches to prevent ICU-acquired weakness. As a pioneer in non-invasive stimulation, it faces limited direct competition but must prove its approach is superior to the status quo.